Arix Bioscience, Russ Mould on the Fed & Paul Hill on Boohoo
Justin Waite
Vox Markets Podcast with Justin Waite
13:17, 10th July 2020

AudioBoom Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here:

On today's Vox Markets Podcast: Arix Bioscience, Russ Mould on the Fed & Paul Hill on Boohoo

Arix Bioscience logo

Jonathan Tobin Managing Director Arix Bioscience (ARIX) FOLLOW discusses one of their portfolio company's Atox Bio which plans a new drug application submission for Q3.

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Russ Mould, Investment Director at stockbroker AJ Bell talks about the FED and their influence on the market.

(Interview starts at 14 minutes 52 seconds)

Paul Hill, full time investor and equity analyst gives his view on:


Rosslyn Data Technologies (RDT) FOLLOW

(Interview starts at 25 minutes 50 seconds)    

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles